Cabaletta Bio, Inc. (CABA)
Last Price$1.7(7.7%)
Market Cap$85.9M
CABA Rating
CABA Quality rating performance
CABA Intrinsic Value
Key Highlights:
As of Mar 03, 2025 CABA Relative Value is $11.0, which is undervalued by 558.1%, compared to current share price of $1.7.
As of Mar 03, 2025 CABA DCF Value is N/A, which is undervalued by N/A, compared to current share price of $1.7.
CABA Share Price History
1W (14.8%)
1M (29.2%)
6M (67.0%)
YTD (92.5%)
1Y (92.4%)
3Y (20.1%)
5Y (89.2%)
10Y (83.3%)
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
CABA Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$85.9M
($81.9M)
$4,010.0K
($83.6M)
Shares Outstanding
51M
Employees
N/A
Growth (CAGR)
N/A
50.4%
12.58%
51.4%
41.74%
Profitability
71.2%
(2,855.4%)
(2,597.6%)
(2,033.6%)
(2,084.0%)
80.2%
Intrinsic Value
$10.5 (528.8% undervalued)
N/A
$10.5
($48.8)
($90.7)
(100.0%)
(5,096.8%)
Valuation (LTM)
Return on Capital
(55.7%)
(49.4%)
(1,229.2%)
(61.0%)
(39.6%)
4,756.2%
4,756.2%
Financial Health
($167.8M)
2.0x
(103.9x)
Dividends
Earnings
May 13, 2025
MISS by 0.0%
MISS by 4.8%
(6.1%)
5 Beat & 5 Miss
CABA Stock Financials
CABA Income Statement Metrics
Annual
Quarterly
LTM
CABA Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
($53.5M) +15.5% YoY
Capital Expenditure (CAPEX)
($687.0K) -72.0% YoY
Free Cash Flow (FCF)
($54.2M) +11.1% YoY
CABA Income Statement Overview
Annual
Quarterly
LTM
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
CABA Balance Sheet Overview
Annual
Quarterly
LTM
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Assets
Liabilities
Total assets
$253.7M
Current assets ($244.5M, 96.4% of total)
$241.2M (95.1%)
$0.0 (0.0%)
Other current assets
$3,241.0K (1.3%)
Non-current assets ($9,160.0K, 3.6% of total)
$0.0 (0.0%)
$7,451.0K (2.9%)
$0.0 (0.0%)
Other non-current assets
$1,709.0K (0.7%)
Financial position
($236.2M)
Cash & Short-term
Investments
Total Debt
CABA Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
CABA Earnings Surprises
Crunching data... Almost there!
CABA Dividends
CABA Dividend Yield
Crunching data... Almost there!
CABA Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with CABA
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$85.9M | 5.8 | $10.5 528.8% undervalued | (92.4%) | $4,010.0K | ($83.6M) | N/A | (2,084.0%) | 71.2% | (1,229.2%) | 8.7% | |
$402.0B | 6.7 | $60.0 32.9% overvalued | (29.6%) | DKK 290.4B | DKK 70.0B | 25.0% | 24.1% | 84.7% | 35.5% | 71.6% | |
$125.5B | 5.7 | $195.0 59.6% overvalued | 14.0% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$74.0B | 6.5 | $1,013.8 48.0% undervalued | (29.5%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 86.7% | 25.0% | 5.7% | |
$38.1B | 5.8 | $109.1 82.5% overvalued | 59.5% | $2,258.9M | ($211.2M) | 127.3% | (9.4%) | 86.8% | (41.3%) | N/A | |
$31.3B | 5.2 | $93.6 61.6% overvalued | 62.3% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$27.1B | 6.3 | $165.8 48.6% undervalued | 24.9% | €3,040.1M | €985.3M | (54.1%) | 32.4% | 84.3% | (41.4%) | 1.3% | |
$14.8B | 5.6 | $46.7 33.6% overvalued | 17.6% | $4,241.2M | $235.2M | 14.8% | 5.5% | 92.3% | (12.7%) | 1.3% | |
$14.6B | 5.9 | $0.5 97.4% overvalued | 327.0% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$14.0B | 7.7 | $427.2 37.8% undervalued | 35.5% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$1,846.9M | 5.4 | $2,805.1 1,137.3% undervalued | 39.9% | $3,316.8M | ($1,009.2M) | 50.5% | (30.4%) | 83.1% | (38.4%) | 32.1% |
FAQ
What is Cabaletta Bio, Inc. (CABA) stock rating?
As of today, Cabaletta Bio, Inc. has a stock rating of 6 (out of 10), which is considered Good.
is Cabaletta Bio, Inc. (CABA) a good stock to buy?
As of today, Cabaletta Bio, Inc. has a Good stock rating, which is 528.8% undervalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 3.2%.